BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

888 related articles for article (PubMed ID: 28989066)

  • 21. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice.
    Jandaghi P; Najafabadi HS; Bauer AS; Papadakis AI; Fassan M; Hall A; Monast A; von Knebel Doeberitz M; Neoptolemos JP; Costello E; Greenhalf W; Scarpa A; Sipos B; Auld D; Lathrop M; Park M; Büchler MW; Strobel O; Hackert T; Giese NA; Zogopoulos G; Sangwan V; Huang S; Riazalhosseini Y; Hoheisel JD
    Gastroenterology; 2016 Dec; 151(6):1218-1231. PubMed ID: 27578530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nestin as a novel therapeutic target for pancreatic cancer via tumor angiogenesis.
    Yamahatsu K; Matsuda Y; Ishiwata T; Uchida E; Naito Z
    Int J Oncol; 2012 May; 40(5):1345-57. PubMed ID: 22246533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CXCL10 and CCL21 Promote Migration of Pancreatic Cancer Cells Toward Sensory Neurons and Neural Remodeling in Tumors in Mice, Associated With Pain in Patients.
    Hirth M; Gandla J; Höper C; Gaida MM; Agarwal N; Simonetti M; Demir A; Xie Y; Weiss C; Michalski CW; Hackert T; Ebert MP; Kuner R
    Gastroenterology; 2020 Aug; 159(2):665-681.e13. PubMed ID: 32330476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
    Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
    Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin 22 Signaling Regulates Acinar Cell Plasticity to Promote Pancreatic Tumor Development in Mice.
    Perusina Lanfranca M; Zhang Y; Girgis A; Kasselman S; Lazarus J; Kryczek I; Delrosario L; Rhim A; Koneva L; Sartor M; Sun L; Halbrook C; Nathan H; Shi J; Crawford HC; Pasca di Magliano M; Zou W; Frankel TL
    Gastroenterology; 2020 Apr; 158(5):1417-1432.e11. PubMed ID: 31843590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.
    Al-Ejeh F; Pajic M; Shi W; Kalimutho M; Miranda M; Nagrial AM; Chou A; Biankin AV; Grimmond SM; ; Brown MP; Khanna KK
    Clin Cancer Res; 2014 Jun; 20(12):3187-97. PubMed ID: 24838526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
    Awasthi N; Yen PL; Schwarz MA; Schwarz RE
    J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-driven like macrophages induced by conditioned media from pancreatic ductal adenocarcinoma promote tumor metastasis via secreting IL-8.
    Chen SJ; Lian GD; Li JJ; Zhang QB; Zeng LJ; Yang KG; Huang CM; Li YQ; Chen YT; Huang KH
    Cancer Med; 2018 Nov; 7(11):5679-5690. PubMed ID: 30311406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance.
    D'Errico G; Alonso-Nocelo M; Vallespinos M; Hermann PC; Alcalá S; García CP; Martin-Hijano L; Valle S; Earl J; Cassiano C; Lombardia L; Feliu J; Monti MC; Seufferlein T; García-Bermejo L; Martinelli P; Carrato A; Sainz B
    Oncogene; 2019 Jul; 38(27):5469-5485. PubMed ID: 30936462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
    Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH
    J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
    Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
    Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
    Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
    Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.
    Awasthi N; Hinz S; Brekken RA; Schwarz MA; Schwarz RE
    Cancer Lett; 2015 Mar; 358(1):59-66. PubMed ID: 25527450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.
    Qian W; Li J; Chen K; Jiang Z; Cheng L; Zhou C; Yan B; Cao J; Ma Q; Duan W
    Life Sci; 2018 Sep; 208():253-261. PubMed ID: 30053447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
    Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
    PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Skeletal Muscle-Derived Irisin Enhances Gemcitabine Sensitivity and Suppresses Migration Ability in Pancreatic Ductal Adenocarcinoma.
    Sugimoto T; Iwagami Y; Kobayashi S; Yamanaka C; Sasaki K; Yamada D; Tomimaru Y; Asaoka T; Noda T; Takahashi H; Shimizu J; Doki Y; Eguchi H
    Ann Surg Oncol; 2024 Jun; 31(6):3718-3736. PubMed ID: 38502294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.
    Wörmann SM; Song L; Ai J; Diakopoulos KN; Kurkowski MU; Görgülü K; Ruess D; Campbell A; Doglioni C; Jodrell D; Neesse A; Demir IE; Karpathaki AP; Barenboim M; Hagemann T; Rose-John S; Sansom O; Schmid RM; Protti MP; Lesina M; Algül H
    Gastroenterology; 2016 Jul; 151(1):180-193.e12. PubMed ID: 27003603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.